
GH Research Investor Relations Material
Latest events

Status Update
GH Research
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from GH Research PLC
Access all reports
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative therapies for psychiatric and neurological disorders. The company's primary area of research is centered on 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a psychoactive compound, which is being developed for treating treatment-resistant depression (TRD) and other mental health conditions. GH Research's leading product candidate, GH001, is an inhalable form of mebufotenin, currently in Phase 2b clinical trials for TRD, as well as in earlier trials for Bipolar II disorder and postpartum depression. Additionally, the company is developing GH002, an intravenous formulation, and GH003, an intranasal product. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
GHRS
Country
🇺🇸 United States